The tumor growth curve data in Figure 3C is consistent with the survival results in Figure 3A. Namely, the CAIR minus CpG/anti-CTLA-4 group is not significantly worse than the full CAIR regimen, while both the CAIR minus anti-CD40/anti-CTLA-4 group and the CAIR minus CpG/anti-CD40 group are significantly worse than the full CAIR regimen. This evidence concerns the gene CTLA4 and neoplasm.